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AbstrAct
In gastric cancer (GC), the main subtypes (diffuse and intestinal types) differ 
in pathological characteristics, with diffuse GC exhibiting early disseminative and 
invasive behaviour. A distinctive feature of diffuse GC is loss of intercellular adhesion. 
Although widely attributed to mutations in the CDH1 gene encoding E-cadherin, a 
significant percentage of diffuse GC do not harbor CDH1 mutations. We found that 
the expression of the actin-modulating cytoskeletal protein, gelsolin, is significantly 
higher in diffuse-type compared to intestinal-type GCs, using immunohistochemical 
and microarray analysis. Furthermore, in GCs with wild-type CDH1, gelsolin expression 
correlated inversely with CDH1 gene expression. Downregulating gelsolin using siRNA 
in GC cells enhanced intercellular adhesion and E-cadherin expression, and reduced 
invasive capacity. Interestingly, hepatocyte growth factor (HGF) induced increased 
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INtrODUctION
Gastric cancer (GC) is one of the most prevalent 
cancer types worldwide. Despite a trend of decreasing 
incidence in developed countries in recent decades [1], 
GC remains one of the leading causes of oncologic deaths 
worldwide, with approximately 11000 deaths in United 
States in 2014 and over 700,000 deaths per annum globally 
[2-4]. Similar to other solid cancers, the occurrence 
of metastasis is an important contributing factor for 
GC mortality. The generation of aggressive epithelial 
carcinomas with disseminative ability frequently involves 
the loss of tight intercellular adhesions as well as increased 
motility and invasiveness [5]. Histopathologically, GC 
is subdivided into two subtypes, diffuse-type GC and 
intestinal-type GC, according to the Laurén classification 
[6]. The intestinal-type GC displays well-differentiated 
tubular or glandular structures, while the diffuse-type GC 
contains infiltrating neoplastic cells and undifferentiated 
or poorly-differentiated glandular structures. The two 
subtypes may also differ in clinical parameters, as 
patients with diffuse-type GC commonly show a higher 
recurrence rate and poorer patient prognosis compared to 
those with intestinal-type GC [7-9]. Despite of histological 
difference, these two subtypes pose different molecular 
profiles, such as E-cadherin expression [10, 11].
The repression of E-cadherin expression, a 
‘master programmer’ of Epithelial Mesenchymal 
Transition (EMT), is a critical event in tumor invasion 
[12]. E-cadherin is a transmembrane protein crucial 
for maintaining intercellular homophilic adhesion of 
epithelial cells. It is responsible for cell adhesion and 
inhibits Wnt/β-catenin-mediated gene transcription, 
thereby maintaining cells in a cohesive, non-motile 
state [5]. The loss of E-cadherin expression is directly 
linked to loss of intercellular adhesion and is associated 
with enhanced invasiveness [13-15], and is therefore an 
indicator of poor prognosis for various cancers, including 
gastric cancer [16]. Unlike the intestinal-type GC, 
diffuse-type GC is associated with loss of expression or 
function of E-cadherin, partly attributable to genomic and 
epigenetic alterations such as inactivating germline and 
somatic mutations in CDH1 [17], loss of heterozygosity 
and promoter hypermethylation [10, 13]. E-cadherin 
expression can also be repressed by various dysregulated 
signal transduction events in both GC subtypes during 
malignant progression as part of the EMT program, 
which activates E-cadherin transcriptional repressors 
[12]. In contrast to mechanisms for the genetic aberration 
of CDH1, the non-genetic molecular mechanisms of 
E-cadherin repression are much less characterized in GC. 
Activation of the HGF-MET signaling pathway 
promotes cell scattering in cancer, and modulates 
other cellular behaviors such as cell invasion, motility, 
proliferation and cell survival [18-20]. The HGF-MET 
signaling is especially relevant in GC which harbors a 
high incidence of MET gene amplification and/or protein 
overexpression [19, 21-24]. HGF together with its receptor 
MET, triggers oncogenic signaling events which result in 
the mesenchymal transformation of tumor cells, resulting 
in attributes which promote tumor spread, including cell-
scattering and invasion. HGF-MET effector pathways, 
including PI3K [25] and MAPK [14, 26], have also been 
implicated in E-cadherin repression and cell scattering 
in various carcinomas. Interestingly, there are evidences 
suggesting the involvement of actin-regulating factors 
in the HGF-MET pathway. It has been reported that 
villin, one of the gelsolin superfamily member, enhances 
HGF-induced motility and morphogenesis of EMT [27]. 
However, whether the gelsolin family members could 
alter E-cadherin to modulate cell motility and scattering 
in response to HGF is currently unknown. In this report 
we describe a novel role of gelsolin, an actin-modulating 
cytoskeletal protein and the founding member of gelsolin 
superfamily, in repression of E-cadherin expression 
through the HGF-MET pathway. 
Gelsolin is required for cytoskeletal turnover 
through its actin-severing and capping activities. By 
virtue of these properties, combined with the ability 
to regulate protease secretion, gelsolin promotes cell 
invasion and migration in various carcinoma cell types 
[28-32]. It is currently unclear whether gelsolin confers 
similar properties in GC. Furthermore, in contrast to its 
role in invasion and migration, the role of gelsolin in 
intercellular adhesion is not well studied. Gelsolin was 
previously reported to interfere with intercellular adhesion 
in canine kidney cells [29] and also in the regulation of β1-
integrin affinity and cell adhesion in leukemic cells [33]. 
In this study we showed that gelsolin inhibits intercellular 
adhesion in GC cells by regulating the expression of 
E-cadherin. We also determined that gelsolin promoted 
GC cell scattering in response to HGF via the PI3K-Akt 
pathway. Our findings reveal a novel function of gelsolin 
gelsolin expression, and gelsolin was essential for HGF-medicated cell scattering 
and E-cadherin transcriptional repression through Snail, Twist and Zeb2. The HGF-
dependent effect on E-cadherin was found to be mediated by interactions between 
gelsolin and PI3K-Akt signaling. This study reveals for the first time a function of 
gelsolin in the HGF/cMet oncogenic pathway, which leads to E-cadherin repression 
and cell scattering in gastric cancer. Our study highlights gelsolin as an important 
pro-disseminative factor contributing to the aggressive phenotype of diffuse GC.
Oncotarget25393www.impactjournals.com/oncotarget
in the mediation of HGF-induced PI3K/Akt activation, 
which leads to E-cadherin repression and scattering of 
GC cells. Hence, gelsolin functions as an important pro-
disseminative protein in GC cells.
rEsULts
Gelsolin expression is increased in diffuse-type 
compared to intestinal-type gastric cancers
We first examined the expression of gelsolin and 
E-cadherin in human GC samples by microarray analysis 
and/or immunohistochemistry (IHC). Microarray analysis 
was conducted on mRNA from 160 gastric tumors, of 
which 68 samples were classified under diffuse-type 
and 92 under intestinal-type GC based on Lauren’s 
classification. The comparison between the 2 GC subtypes 
showed higher gelsolin mRNA expression in diffuse-type 
GCs (p = 0.03), based on unpaired student’s t-test analysis 
(Figure 1A). Gelsolin expression was further investigated 
by IHC in 118 parrafin-embedded primary gastric tumors 
(matched with adjacent normal tissues) comprising 46 
diffuse-type and 72 intestinal-type gastric tumors. High 
expression of gelsolin was observed in the muscularis 
propria as previously reported [34, 35]. In normal gastric 
mucosa, gelsolin staining exhibited a heterogenous 
and gradient pattern, where the surface mucosal cells 
expressed high levels of gelsolin and the deeper glands 
showed undetectable to low expression (Suppl. Figure 
1A). Interestingly, whilst the majority of intestinal-type 
GCs stained poorly for gelsolin, diffuse-type tumors 
expressed higher gelsolin levels (Figure 1B). In a small 
proportion of tumors, mixed features comprising both 
diffuse and intestinal-type tumor tissues within the same 
tumor were observed. In these ‘mixed-type GCs’ the 
diffuse component also showed more intense gelsolin 
staining compared to the intestinal component (Figure 1B). 
Gelsolin expression in diffuse-type GCs was significantly 
increased above that observed in intestinal-type GCs, as 
reflected in the Gelsolin Expression Index which was 
calculated based on IHC staining intensities (p = 0.0015, 
Unpaired t-test) (Figure 1C). Overall, the observations of 
high gelsolin expression in GC tumors displaying diffusely 
infiltrative phenotype and low gelsolin expression in GC 
tumors with cohesive morphology are indicative of a 
positive association between gelsolin and gastric cancer 
invasiveness. 
Gelsolin is increased in intestinal-type GC 
metastatic to lymph nodes
Recently we reported that gelsolin expression was 
increased in the liver metastases of a subset of colon 
cancer patients [28]. We sought to investigate if a similar 
correlation exists in the intestinal-type primary tumors 
and their metastases, since the latter generally expresses 
relatively low gelsolin levels. 20 intestinal-type lymph 
node metastases were examined for gelsolin expression 
by IHC. The majority of lymph node metastases (17 of 
20 tumour pairs) expressed significantly higher gelsolin 
levels compared to their corresponding primary tumors 
(p = 0.004, Paired t-test) (Supp. Figure 1B-1D). Our 
data suggests that increased gelsolin expression may 
also favour the development of metastases in intestinal-
type GC, and is consistent with the reported pro-invasive 
function of gelsolin [28, 29].
Expression of gelsolin inversely correlates with 
wild-type E-cadherin
E-cadherin, an important protein encoded by CDH1 
gene to mediate cell adhersion, has been reported to be 
commonly mutated in diffuse-type gastric cancer to 
contribute to cancer dissemination (6,35-37). We examined 
the association of gelsolin and E-cadherin expression. 
Three gastric cancer cohorts from GEO and TCGA were 
analysed (Figure 2). There was a significant, negative 
correlation between gelsolin and CDH1 for patient 
samples with wild-type CDH1 across all three cohorts. 
This correlation was not found for patient samples with 
silenced or mutated CDH1. Therefore, the expression of 
gelsolin inversely correlates with wild-type E-cadherin but 
not with its mutated form. Our data suggests that gelsolin 
may be involved in regulating functional E-cadherin 
expression.
Loss of gelsolin abrogates invasion of gastric 
cancer cells and promotes E-cadherin-dependent 
intercellular adhesion of gastric cancer cells
Since diffuse GC tissues and metastatic GC cell 
lines revealed a possible correlation between gelsolin and 
tumor progression and invasiveness, we examined the 
effect of gelsolin on invasion in two gastric cancer cell 
lines with high gelsolin expression, MKN28 and AGS. We 
used siRNA knockdown of gelsolin to decrease protein 
expression in both cell lines by > 95% (Supp. Figure 
2A), and this corresponded with a significant reduction in 
invasive capacity through matrigel in response to a serum-
concentration gradient (Supp. Figure 2B). There were no 
changes in cell proliferation or cell death when gelsolin 
levels were reduced by siRNA transfection (Supp. Figure 
2C-2D). These findings provide evidence that gelsolin 
is important for the invasiveness of gastric cancer cells, 
consistent with previous reports on other tumor types [28, 
29]. 
The loss or reduction of intercellular adhesion is 
a hallmark of malignancy which is closely associated 
with a propensity for invasion and distant metastasis 
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Figure 1: Increased Gelsolin expression in diffuse-type gastric cancer. A. Relative gelsolin gene expression in diffuse-type and 
intestinal-type gastric cancer. N = 68 (Diffuse-type), N = 92 (Intestinal-type). B. IHC staining of gelsolin expression in intestinal, diffuse 
and mixed gastric cancer tissues. C. Gelsolin expression index in diffuse and intestinal type gastric cancers. N = 46 (Diffuse-type), N = 72 
(Intestinal-type). Score was calculated by the product of staining intensity and corresponding % positivity, where intensity ranges from 0 
(no observable staining) to 3 (intense staining). Paired T-test was used to compute p-value shown. 
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[13]. To determine the effect of gelsolin on intercellular 
adhesion, cell aggregation assays were conducted by 
culturing GC cells in soft agar for 24 hours. The semi-
solid substrate prevents the adherence of cells and reduces 
cell movement, thereby allowing the relative assessment 
of the strength of intercellular adhesion (De Corte et 
al., 2002). As E-cadherin is a prominent epithelial cell 
adhesion molecule mediating tight intercellular adhesion, 
it is an important mediator of cellular aggregation. We 
thus performed the cell aggregation experiments using 
E-cadherin-positive MKN28 and E-cadherin-deficient 
AGS cells as a negative control (Figure 3A). Western 
blot was used to confirm the knockdown efficiency of 
gelsolin siRNA (Figure 3B). We observed that whilst 
control siRNA-transfected MKN28 cells were loosely 
scattered in small clusters, gelsolin siRNA-transfected 
cells formed large aggregated cell clusters, indicating 
that the loss of gelsolin enhanced intercellular adhesion 
Figure 2: Gelsolin expression inversely correlates with wild-type E-cadherin expression. A. GSE15460 (75 samples with 
silenced or mutated CDH1 & 181 samples of wild-type CDH1), B. GSE65801 (11 samples with silenced or mutated CDH1 & 21 samples 
of wild-type CDH1) and C. TCGA STAD (32 samples with silenced or mutated CDH1 & 186 samples of wild-type CDH1) for silenced or 
mutated CDH1 (left) and wildtype CDH1 (right). Green dashed lines are the linear regression results.
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Figure 3: Loss of Gelsolin promotes E-cadherin-dependent intercellular adhesion of gastric cancer cells. A. Western 
blot of basal E-cadherin and Gelsolin protein levels in MKN28 and AGS cells. B. MKN28 and AGS cells were transfected with control 
scrambled RNA or siGelsolin RNA. Western blot was conducted after 48h to check efficiency of knockdown. C. Cell aggregation assay 
on soft agar was conducted with MKN28 cells transfected with control scrambled RNA or siGelsolin RNA. Cells were also incubated with 
function-blocking E-Cadherin antibodies. Images are representatives from three independent experiments. D. Cell aggregation assay was 
conducted with AGS cells transfected with control scrambled RNA or siGelsolin RNA. Images are representatives from three independent 
experiments. 
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of MKN28 cells (Figure 3C). Furthermore, we observed 
that the cellular aggregation of MKN28 cells induced by 
gelsolin siRNA was abrogated by treatment of cells with 
function-blocking E-cadherin antibodies, where cells 
then assumed loose aggregation patterns similar to the 
control siRNA-transfected cells (Figure 3C). Hence, the 
cellular aggregation resultant upon the loss of gelsolin is 
potentially associated with enhanced E-cadherin function, 
without which cells consequently become loosely 
scattered. In contrast, gelsolin depletion in E-cadherin-
negative AGS cells did not affect cellular aggregation 
(Figure 3D). Our data therefore suggests that gelsolin only 
influences infiltrative behavior of GC cells with functional 
E-cadherin.
Loss of gelsolin increases E-cadherin expression 
in gastric cancer cells
The loss of intercellular adhesion is frequently 
attributed to the downregulation and/or dyslocalization 
of cell adhesion molecules such as E-cadherin [36, 37]. 
We observed that siRNA mediated depletion of gelsolin 
in GC cells increased the protein levels of E-cadherin 
by more than 2 folds in MKN28 cells (Figure 4A). The 
increase in E-cadherin by gelsolin knockdown was 
confirmed by using two siRNA targeting gelsolin (Supp 
Figure 3). Similarly, knockdown of gelsolin induced the 
protein expression of E-Cadherin in MKN7 and MKN74 
cells (Supp Figure 4A&4B), supporting a role of gelsolin 
in regulating E-Cadherin expression. Concomitantly, 
E-cadherin expression at intercellular junctions based 
on immunofluorescence detection was increased in the 
gelsolin-depleted cells compared to control siRNA-
transfected cells (Figure 4B). These results corroborate the 
cellular aggregation data and suggest that loss of gelsolin 
in GC cells promotes increased E-cadherin expression and 
its localization to intercellular junctions, resulting in an 
increased ability of the cancer cells to aggregate. 
We next assessed whether the gelsolin-mediated 
E-cadherin downregulation is also observed at the 
transcriptional level. We observed that siRNA depletion 
of gelsolin significantly increased E-cadherin expression 
at the mRNA level, using real-time PCR. To determine 
if depletion of gelsolin increased E-cadherin expression 
via transcriptional activation, we examined the effect 
of gelsolin depletion on the expression of well-known 
E-cadherin transcriptional repressors, namely Snail, Slug, 
Twist1, ZEB-1 and ZEB-2. We observed that gelsolin 
depletion reduced the mRNA levels of Snail, Twist and 
ZEB-2, concordant with an increase in E-cadherin mRNA 
expression upon gelsolin depletion in both MKN28 and 
MKN74 cells (Figure 4C-4D, Supp. Figure 4C). Hence, 
gelsolin may be a novel repressor of E-cadherin expression 
by modulating the expression of Snail, Twist and ZEB-2. 
Gelsolin is induced by hepatocyte growth 
factor (HGF) and is essential for HGF-induced 
E-cadherin downregulation and cell scattering
We have thus far observed that gelsolin is an 
important repressor of E-cadherin expression in GC. The 
activation of HGF-MET signaling is a well-established 
stimulus leading to decreased expression of E-cadherin 
and cell scattering in GC cells [38]. We therefore 
proceeded to determine whether gelsolin mediates HGF-
induced E-cadherin repression. For these experiments, we 
utilized MKN28, MKN74, and TMK-1 GC cell lines, all 
of which express c-MET and are able to respond to HGF-
induced growth activation. 
We observed that expression of gelsolin mRNA and 
protein were increased following treatment with HGF in 
MKN28, MKN74, and TMK1 cells (Figure 5A-5D, Supp. 
Figure 6A), an association that was hitherto unreported. 
Expectedly, HGF promoted partial loss of intercellular 
adhesion and a mesenchymal cell phenotype in the three 
cell lines (Figure 4E, Supp. Figure 5A, and Supp. Figure 
6B). Notably, the reduction in intercellular adhesion was 
more distinct in MKN28 and MKN74, which normally 
exhibit an epithelial morphology compared to TMK1, 
which assumes a slightly scattered appearance in culture. 
HGF-induced phenotypic changes in MKN28, MKN74 
and TMK1 cells were abrogated by siRNA reduction of 
gelsolin levels, indicating that gelsolin is necessary for 
HGF to promote GC cell scattering (Figure 4E, Supp. 
Figure 5A, and Supp. Figure 6B). HGF stimulation 
repressed E-cadherin protein, consistent with the reported 
effects of HGF, and this reduction was abrogated by 
gelsolin depletion (Figure 5F, Supp. Figure 5B, and 
Supp. Figure 6C), indicating that gelsolin modulates 
the HGF-induced repression of E-cadherin expression. 
Importantly, the levels of gelsolin and E-cadherin 
correlated with the morphological changes observed, 
further confirming the role of gelsolin in HGF-induced cell 
scattering. Furthermore, depletion of gelsolin impaired 
the cellular response to HGF-induced gene transcriptional 
changes, which includes repression of E-cadherin and a 
concomitant increase in the mRNA expression levels of 
Snail, Twist and ZEB-2 (Figure 5G and Supp. Figure 
5C). The effect of gelsolin knockdown on HGF-induced 
transcription was also observed in MKN74 cells, where 
HGF-induced expressions of Snail, Twist, ZEB-1 and 
ZEB-2 were significantly inhibited by silencing gelsolin 
(Supp. Figure 6D-6E). Taken together our data indicates 
that gelsolin is a downstream effector of HGF-induced 
E-cadherin repression and cell scattering.
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Figure 4: Loss of Gelsolin increases E-Cadherin expression in gastric cancer cells. A. MKN28 cells were transfected with 
control scrambled RNA or siGelsolin for 48h. Left: Western blot of E-Cadherin expression levels after transfection. Right: Densitometric 
analysis of E-Cadherin protein levels normalized to GAPDH protein levels after transfection. Values represent mean ± SD, n = 3, *P < 0.05 
vs. control. B. Immunofluorescence staining of E-Cadherin expression levels in MKN28 cells after transfection with control scrambled 
RNA or siGelsolin for 48h. Images are representatives from three independent experiments.C. E-Cadherin mRNA levels in MKN28 cells 
after transfection with control scrambled RNA or siGelsolin for 48h, normalised to GAPDH mRNA levels. Values represent mean ± SD, n 
= 3, *P < 0.05 vs. control. D. Snail, Slug, Twist, ZEB-1 and ZEB-2 mRNA levels in MKN28 cells after transfection with control scrambled 
RNA or siGelsolin for 48h, normalised to GAPDH mRNA levels. Values represent mean ± SD, n = 3, *P < 0.05 vs. control. 
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Figure 5: Gelsolin mediates HGF-induced E-cadherin downregulation and cell scattering of gastric cancer cells. A. 
Left: Western blot analysis of gelsolin levels in MKN28 cells treated with HGF for 48h. Right: Densitometric analysis of gelsolin protein 
levels in MKN28 cells treated with HGF for 48h. Values represent mean ± SD, n = 3, *P < 0.05 vs. control. B. Gelsolin mRNA levels in 
MKN28 cells treated with HGF for 48h, normalized against GAPDH levels. Values represent mean ± SD, n = 3, *P < 0.05 vs. control. C. 
Left: Western blot analysis of gelsolin levels in TMK1 cells treated with HGF for 48h. Right: Densitometric analysis of gelsolin protein 
levels in TMK1cells treated with HGF for 48h. Values represent mean ± SD, n = 3, *P < 0.05 vs. control. D. Gelsolin mRNA levels in 
TMK1cells treated with HGF for 48h, normalized against GAPDH levels. Values represent mean ± SD, n = 3, *P < 0.05 vs. control. E. 
Light microscopy images of MKN28 cells transfected with ctsi or siGelsolin and treated with HGF for 48h (x100 magnification). Images 
are representatives from three independent experiments. F. Western blot of MKN28 cells transfected with ctsi or siGelsolin and treated with 
HGF for 48h and blotted for E-Cadherin protein expression. G. E-cadherin mRNA levels in MKN28 cells transfected with ctsi or siGelsolin 
and treated with HGF for 48h, normalized against GAPDH mRNA levels. Fold changes of mRNA compared to ctsi transfected cells were 
presented. Values represent mean ± SD, n = 3, *P < 0.05 vs. control. H. Snail, Twist and Zeb2 mRNA levels in MKN28 cells transfected 
with ctsi or siGelsolin and treated with HGF for 48h, normalized against GAPDH mRNA levels. Fold changes of mRNA compared to ctsi 
transfected cells without HGF treatment were presented. Values represent mean ± SD, n = 3, *P < 0.05 vs. control. 
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Figure 6: Gelsolin mediates HGF-induced E-cadherin downregulation via PI3K-Akt pathway. A. Western blot of MKN28 
cells transfected with ctsi or siGelsolin before treatment with HGF for 0-120 min and analyzed for gelsolin, phosphorylated Akt and Akt 
protein levels. B. Western blot of MKN28 cells pre-incubated with 10, 20 and 40µM LY294002 for 1h before treatment with HGF for 
48h and analyzed for gelsolin, phosphorylated Akt and Akt protein levels.C. Western blot of MKN28 cells treated as in A. and analyzed 
for protein levels of EMT markers E-Cadherin, Zeb2, Twist and Snail. D. Proximity ligation assay of MKN28 cells treated with 10ng/
ml HGF for 1h and stained with PI3K and Gelsolin antibodies. Top: Microscopy images of cells. Red spots are representative of the 
interactions between PI3K and Gelsolin, each red spot is equivalent to one molecular interaction. Nuclei are stained with DAPI. Images 
were acquired using a fluorescence microscope at x400 magnification. Scale Bar = 20µm. Bottom: Quantitative analysis of number of 
molecular interactions counted from 3 representative images taken at random fields from 2 experiments. Values represent mean ± SD, n 
= 2, *P < 0.05 vs. untreated. E. Model of HGF-induced cell scattering and loss of intercellular adhesion in gastric cancer cells involving 
gelsolin-PI3K-Akt pathway.
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Gelsolin mediates the HGF-induced repression of 
E-cadherin via PI3K-Akt pathway
As the binding of HGF to c-MET receptors initiates 
multiple intracellular signaling events, we sought to 
delineate the specific downstream pathway(s) mediating 
E-cadherin repression in MKN28 and TMK-1 cells, 
including the PI3K-Akt and MEK-MAPK pathways which 
have been previously implicated in the downregulation 
of E-cadherin [14, 26, 39]. Cells were serum-starved 
for 24 hours before treatment with 10ng/mL of HGF. 
Western blot analysis showed that HGF treatment resulted 
in activation of the PI3K-Akt pathway, as evident from 
the increased phosphorylated Akt (pAkt), which was 
sustained for at least 120 minutes after HGF stimulation 
(Figure 6A and Supp. Figure 7A). To determine whether 
gelsolin modulated this HGF-stimulated signaling, cells 
were depleted of gelsolin by use of siRNA, followed by 
serum-starvation and stimulation with HGF. As shown in 
Figure 5A and Supp. Figure 4A, gelsolin siRNA depletion 
resulted in inhibition of Akt phosphorylation in both 
MKN28 and TMK1, indicative that gelsolin is a modulator 
of the HGF-induced PI3K-Akt pathway in GC cells. 
To determine if the increased expression of gelsolin 
stimulated by HGF is dependent on PI3K, LY294002 
was used as a specific inhibitor of PI3K. The increase 
in gelsolin expression upon HGF stimulation was 
abrogated by dose-independent increases in LY294002. 
Phosphorylation of Akt was used as a measure of the 
inhibitory effect of LY294002, where increasing doses 
inhibited the levels of p-Akt (Figure 6B). Simultaneously, 
HGF treatment resulted in a repression of E-cadherin 
corresponding with an upregulation of E-cadherin 
transcriptional repressors Snail, Twist and ZEB-2 in 
MKN28 and TMK-1 cells. These changes in gene 
expressions were abrogated by LY294002, indicating that 
the PI3K-Akt signaling pathway mediated HGF-dependent 
E-cadherin repression (Figure 6C). 
It was reported previously that gelsolin interacts 
with PI3K in a complex in osteoclast podosomes [40] and 
stimulates PI3K activity [41]. Using a proximity ligation 
assay which detects protein interactions in cells in situ, 
we observed an increased association between gelsolin 
and PI3K in MKN28 cells upon HGF treatment (Figure 
6D). Whether this physical interaction is required for 
PI3K activity (and therefore the activation of PI3K-Akt 
pathway) is of interest for future studies. Taken together 
our findings strongly suggest that gelsolin promotes the 
loss of E-cadherin by functioning as a mediator of the 
HGF-dependent PI3K-Akt pathway, thus regulating cell 
scattering and intercellular adhesion (Figure 6E). 
DIscUssION
During the course of dissemination, epithelial 
cells may undergo the EMT program, during which 
closely-associated, non-invasive cells transform into 
loosely-associated, migratory and invasive cells. 
E-cadherin expression is frequently lost or reduced 
during this phenotypic transition [12, 38]. Lower 
E-cadherin levels were observed in the diffuse-type GC 
compared to intestinal-type GC, which correlated with 
the morphological characteristics and consistent with the 
varying aggressiveness of these two subtypes [10, 42]. 
Somatic alterations in E-Cadherin have been found in 
approximately 30% of GC, with frequencies ranging from 
3-50% in sporadic diffuse-type GC [43, 44]. Therefore, 
besides genetic aberrations leading to downregulation 
of E-cadherin, non-genetic molecular mechanisms 
contributing to loss of E-cadherin function have become 
of increasing importance. In this study we show that the 
cytoskeletal protein, gelsolin, is an important determinant 
of GC invasion and cell scattering by mediating 
E-cadherin repression via the HGF-PI3K-Akt signaling 
pathway.
Gelsolin was found to be upregulated in diffuse-
type GC compared to intestinal-type GC, indicating that 
gelsolin is associated with a more infiltrative phenotype. 
Interestingly, we also observed a differential pattern 
of gelsolin expression in the intestinal-type primary 
tumors expressing low gelsolin. It was found that 
gelsolin expression was higher in a subset of lymph node 
metastases compared to their primary intestinal tumors. 
The evidence is also concordant with data showing higher 
gelsolin levels in cell lines derived from metastatic sites, 
as well as a previous reports documenting increased 
gelsolin expression in tumor metastases [28, 45]. It is 
currently unclear whether gelsolin has distinct functions in 
the pathogenesis of these two subtypes at different stages, 
especially with respect to their disseminative potential.
Our initial in vitro data revealed a decrease in 
invasiveness and loss of cellular aggregation upon gelsolin 
depletion in GC cells. This is corroborated by previous 
reports that gelsolin is required for tumor cell invasion 
and cellular aggregation in various carcinomas [33, 46, 
47]. Since the effect of gelsolin on cellular aggregation is 
determinant upon the presence of functional E-cadherin, 
we investigated the possible effects of gelsolin on 
E-cadherin expression. We observed that there was an 
inverse correlation of gelsolin with E-cadherin expression, 
where depletion of gelsolin led to increases in E-cadherin 
expression, therefore contributing to enhanced cellular 
aggregation and perturbed cell scattering properties. This 
is accompanied by decreases in E-cadherin transcriptional 
repressors Snail, Twist and Zeb-2. Perturbations of 
E-cadherin following gelsolin overexpression has been 
previously reported in cardiomyocytes [48], supporting 
our inverse correlation between gelsolin and E-cadherin. 
Besides functioning as actin-binding proteins, nuclear 
roles of gelsolin in regulation of transcription have 
been reported. Gelsolin and its family members 
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such as Flightless-I (FliI), have been shown to act as 
transcriptional coactivators of nuclear receptors such as 
estrogen receptor, androgen receptor and glucocorticoid 
receptor [49], and FliI was found to alter transcription 
of genes involved in β-catenin signaling such as cyclin 
D1 [50]. These provide support for gelsolin as a possible 
transcriptional regulator of E-cadherin. However, the exact 
mechanism of how gelsolin inhibits nuclear transcription 
of E-cadherin remains to be elucidated. 
We also found that HGF activates the PI3K-Akt 
pathway in GC cells, leading to induction of E-cadherin 
repressors Snail, Twist and ZEB-2, and concomitant 
downregulation of E-cadherin. Silencing of gelsolin 
blocked the upregulation of E-cadherin transcriptional 
repressors Snail, Twist and Zeb2, and the repression of 
E-cadherin in response to HGF, showing the critical role 
of gelsolin in cellular response to c-MET activation. 
Interestingly, siRNA depletion of gelsolin resulted in 
a stark inhibition of Akt phosphorylation in response 
to HGF, indicating that gelsolin expression is pivotal 
to the activation of PI3K-Akt pathway under HGF-
MET signaling transduction event. In contrast, little or 
no p-Akt was detected in TMK-1 cell line following 2 
hours of HGF treatment, corresponding with a sustained 
effect of gelsolin siRNA. The delay in gelsolin induction 
in response to HGF in TMK-1 may be attributed to its 
relatively low expression of MET [51], in contrast to 
MKN28 which expresses higher levels of c-MET [52]. 
Activation of HGF signaling also led to an induction 
of gelsolin, a phenomenon that decreased upon inhibition 
of PI3K, suggesting that gelsolin expression may be 
regulated by PI3K. Restoration of E-cadherin levels 
were also observed, which is consistent with an earlier 
report [25]. The reduction of gelsolin and restoration 
of E-cadherin following PI3K inhibition blocked the 
induction of E-cadherin transcriptional repressors 
upon HGF treatment, suggesting that gelsolin-PI3K-
Akt signaling could be involved in regulating the EMT 
transcription factors. A previous study reported that 
gelsolin inhibits E-cadherin-mediated cell aggregation in 
transformed canine cells, but the authors found no effect 
of gelsolin on the integrity of E-cadherin-catenin adherens 
complex [29]. Consistent with our findings, an earlier 
study showed that inhibition of PI3K represses gelsolin 
protein levels and decreased migration and invasion of 
hepatocarcinoma cells, providing further evidence for 
gelsolin’s involvement in the PI3K-Akt pathway [53]. 
This finding also strongly supports an oncogenic role for 
gelsolin, since the PI3K-Akt axis is a major downstream 
pathway that is activated by oncogenic signaling mediated 
by several other receptor tyrosine kinases besides c-MET, 
such as EGFR and ERBBs [54]. 
Gelsolin has been shown to physically associate 
with PI3K [40, 55] and promote its activity [41]. 
Interestingly we observed a greater degree of interaction 
between gelsolin and PI3K in the presence of HGF, 
which correlated with higher Akt phosphorylation. 
Further studies are warranted to confirm whether gelsolin 
influences Akt phosphorylation through its physical 
association with PI3K, and whether gelsolin exerts similar 
effects on PI3K activation mediated by other growth factor 
receptor signal transduction events.
In summary, our findings have shown that gelsolin 
confers disseminative properties in GC cells, by promoting 
cell invasion as well as functioning as a determinant in 
the HGF-PI3K-Akt signaling pathway which mediates 
E-cadherin downregulation and cell scattering. Although 
further molecular insights of these processes still await 
to be elucidated, our study have shed more light on the 
oncogenic functions of gelsolin involved in driving GC 
dissemination. Combined with the clinical data showing 
higher gelsolin levels in diffuse and metastatic GC, a 
novel role for gelsolin as a potential biomarker in disease 
diagnosis and target for therapy is unraveled. 
MATERIALS AND METHODS
Human samples
Primary gastric tumors were obtained from National 
Cancer Centre, Singapore with approvals from Research 
Ethics Review Committee, and signed patient informed 
consent. Total RNA was extracted using Qiagen RNA 
extraction reagents (Qiagen, Venlo, Limburg, Netherlands) 
according to the instructions of the manufacturer and 
hybridized to Affymetrix Human Genome U133 plus 
Genechips (HG-U133 Plus 2.0, Affymetrix, Santa Clara, 
CA, USA). Raw data obtained after chip-scanning was 
pre-processed using the MAS5 algorithm (Affymetrix). 
Data were subjected to Log 10 transformation followed 
by median-centered across all probe sets for each sample 
(primary tumor). The centering is such that the median 
of expression in each sample is zero. 160 were classified 
by pathological diagnosis into diffuse-type GCs (68 cases) 
and intestinal-type (92 cases).
Formalin-fixed and paraffin-embedded (FFPE) 
primary tumor and matched normal tissue samples from 
118 patients with gastric cancer were obtained from the 
Department of Pathology at the National University 
Hospital System, Singapore, under an institutionally 
approved protocol. 
Immunohistochemistry and scoring methods
Briefly, 5µm thick tumor sections were 
deparaffinized, boiled in Antigen Unmasking Solution 
(Vector Laboratories, Inc Burlingame, CA, USA) at 95oC 
for 10 minutes and blocked with hydrogen peroxide for 
5 minutes before primary antibody incubation overnight 
at 4oC. Both primary anti-gelsolin (Abcam, Cambridge, 
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England, UK) and anti-E-cadherin (Millipore, Darmstadt, 
Germany) monoclonal antibodies were used at a dilution 
of 1:500. The antibody used was previously determined 
to be specific for gelsolin by western blots of protein 
lysates from several human cell lines, as well as cell 
lines transfected with a gelsolin-expressing plasmid. All 
other steps were performed using the avidin-biotinylated 
horseradish peroxidase complex method (Envision+, 
DAKO, Glostrup, Denmark). Samples were incubated 
with DAB+ chromogen (DAKO, Glostrup, Denmark) 
for 3 minutes and subsequently counterstained with 
hematoxylin. Gelsolin expressions was quantified as 
described previously [56, 57]. The staining score was 
expressed as the Gelsolin Expression Index ( = intensity X 
corresponding % positivity), where intensity ranges from 
0 (no observable staining) to 3 (intense staining), and % 
positivity ranges from 0-100%. The normal epithelial cells 
adjacent to tumor cells (if available) were used as scoring 
references. Paired T-test was used for statistical analysis.
Bioinformatical analysis of gelsolin and 
E-cadherin expression
Three gastric cancer cohorts were taken from 
GEO database (http://www.ncbi.nlm.nih.gov/gds) and 
TCGA (https://tcga-data.nci.nih.gov/tcga/). The two GEO 
datasets with the GEO accession numbers of GSE15460 
and GSE65801 [58] were generated using microarray 
technologies, while the third cohort was the RNA-seq 
data of the TCGA Stomach Adenocarcinoma (STAD) 
set. The raw CEL files were downloaded for the two 
microarray datasets, and the gene expression intensities 
were extracted by RMA and further normalized by the 
Cross-Correlation method [59]. For TCGA RNA-seq data, 
raw counts of Level 3 were downloaded and only non-
intestinal gastric adenocarcinoma including diffuse-type 
were used as the third cohort. The RNA-seq counts were 
normalized using the total numbers of mappable reads 
across all samples. All normalized data were then log2-
transformed, and normalized log2 transformed expression 
data for GSN and CDH1 were subsequently used for the 
expression correlation study.
cell lines
MKN7, MKN28, MKN74, TMK1, AGS, are 
commercially-available cell lines from ATCC, Manassas, 
VA, USA.
Cell culture and drug treatment
Cell lines MKN7, MKN 28, MKN74 and AGS 
were cultured in RPMI-1640 (Sigma, St. Louis, MO, 
USA) and TMK1 in DMEM, supplemented with 10% 
fetal bovine serum (FBS; Gibco, Grand Island, NY, USA) 
and 1% penicillin streptomycin (Gibco). All cell lines are 
maintained in a humidified 370C incubator with 5% CO2. 
Cells were plated at similar density prior to treatments. 
Human recombinant hepatocyte growth factor (HGF) was 
purchased from Sigma while PI3K inhibitor LY294002 
and was purchased from Promega, Madison, WI, USA. 
Cellular aggregation
Aggregation assays were performed as described 
previously [29]. After 24 hours of siRNA transfection, 
cells were detached and seeded on top of a semi-solid 
agar coated 96-well plate in the presence or absence of 
25µg/ml of E-cadherin neutralizing monoclonal antibody 
(Millipore). Aggregation formation was evaluated after 
24 hours under an inverted phase-contrast microscope 
(ZEISS, Jena, Germany). 
Invasion assay
BD Matrigel basement membrane matrix (BD 
Biosciences, Franklin Lakes, NJ, USA) was diluted and 
coated onto the upper chamber of transwells (Corning 
Costar, Tewksbury MA, USA) according to manufacturer’s 
instructions. Cells were transfected with siRNA duplex 
for 24 hours, then cultured in serum-free medium for 24 
hours. Next, they were seeded onto the upper chamber 
of the matrigel-coated transwell containing serum-free 
medium. Complete medium with 10% FBS was added 
to the lower chamber. Cells were allowed to migrate at 
37oC in a humidified incubated supplemented with 5% 
CO2 for 24 hours. Cells in the upper chamber were then 
removed and the upper side of the membrane thoroughly 
cleaned. Invading cells were fixed and stained with either 
crystal violet or propidium iodide. Invaded cells stained 
with propidium iodide were counted using the inverted 
fluorescent microscope in at least 10 representative fields.
Western blot analysis
Cells were harvested and protein extracted using 
RIPA lysis buffer with protease inhibitor cocktail mix 
(Roche Diagnostics, Mannheim, Germany). Proteins 
were separated by electrophoresis under denaturing and 
reducing conditions. Monoclonal antibodies against 
gelsolin (Abcam), E-cadherin (Millipore), AKT and 
phosphorylated Akt, Erk and phosphorylated Erk (Cell 
Signaling, Beverly, MA, USA) and GAPDH (Santa Cruz 
Biotechnology Inc, Dallas, TX, USA) were used. 
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Cell proliferation ELISA
Cells were transfected with siRNA duplex for 24 
hours, then re-seeded in a 96-well plate in the medium at 
a density of 1000 cells/well and left overnight to attach. 
The following day, BrdU were added to each well. Cells 
were fixed and stained after 24 hours according to the 
manufacturer’s instructions (Cell Proliferation ELISA for 
BrdU; Roche, Basel, Switzerland). Colorimetric analysis 
was performed with an ELISA plate reader (Biochrom 
Asys UVM 340; Biochrom, Holliston, MA, USA). 
Cell death
Cells were transfected with siRNA duplex for 72 
hours, and then trypsinized and resuspended in PBS, 
followed by fixation in ice-cold 70% ethanol. Cellular 
DNA was stained with propidium iodide solution (PBS 
containing 50mg/ml propidium iodide, 0.1% Triton 
X-100 and 100mg/ml RNaseA) and analyzed using FACS 
Vantage SE Flow Cytometry system (Becton Dickinson, 
NJ, USA). 
Gene silencing by RNA interference
Stealth siRNA targeting gelsolin was purchased 
from ThermoFisher Scientific (HSS104526 of siGel1 and 
HSS104524 of siGel2. siGel1 was used as gelsolin siRNA 
unless otherwise stated). 10nM of the Stealth siRNA, 
complexed with lipofectamine, was used to silence 
gelsolin expression in cells. Medium GC control siRNA 
which matched the GC content of the gelsolin siRNA used 
was included as controls. Cells were harvested at 72 hours 
and treated as used in other assays as described.
Real-time PCR assay
Total RNA from cell lines were isolated from 
cultures of each experiment group with the Qiagen 
RNeasy kit as described by the manufacturer. 500-1000ng 
of cDNA was used for amplification, carried out on the 
7500 Fast Real-Time PCR System. The thermal cycling 
conditions were as follows: one cycle at 95oC for 10 
minutes, followed by 40-50 cycles of denaturation at 
95oC for 15 seconds and annealing extension at 60oC for 
1 minute. The specific primers used were designed by 
manufacturer to detect Gelsolin, E-cadherin, Snail, Slug, 
Twist, ZEB-1 and ZEB-2. Glyceraldehyde-3-phosphate 
(GAPDH) was including as an internal control. All 
reagents are from Applied Biosystems (Foster City, CA, 
USA).
Proximity ligation assay
The mouse/rabbit red starter Duolink kit (Olink, 
Uppsala, Sweden) was used for this experiment. The 
cells were seeded on glass slides and treated with 10ng/
ml HGF for one hour. Cells were then fixed with 4% 
paraformaldehyde for 15 minutes at room temperature and 
permeabilized with 0.25% Triton in PBS for 10 minutes at 
room temperature. After permeabilization the cells were 
incubated in the blocking buffer (provided with the kit) 
for 30 minutes at 37°C. Cells were then incubated with 
the primary antibodies against gelsolin (Abcam) and 
PI3K (Cell Signaling, Beverly, MA, USA) diluted in the 
antibody diluents for overnight at 4oC. On the next day, 
cells were washed in Buffer A 3 times for 15 minutes and 
incubated with the PLA probes for one hour at 37°C. This 
was followed by a 10 and 5 minutes wash in Buffer A. 
Ligation was carried out at 37°C for one hour followed 
by a 10 and 5 minutes wash in Buffer A. The cells were 
then incubated with the amplification mix for two hours 
at 37°C in a darkened humidified chamber. After washing 
with 1x Buffer B for 10 minutes followed by a 1 minute 
wash with 0.01X buffer B, the cells were stained with 
DAPI for 2 minutes and mounted onto microscope slides 
using mounting media. Cells were then viewed under a 
fluorescence microscope.
Statistical analysis
 Non-paired Student’s t-test was used to compare 
the means of two groups and P < 0.05 was considered 
statistically significant.
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